Page 78 - Read Online

Casolino et al. Hepatoma Res 2021;7:76 https://dx.doi.org/10.20517/2394-5079.2021.79 Page 21 of 23

54. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1
in intrahepatic cholangiocarcinomas. Nat Genet 2013;45:1470-3. DOI PubMed PMC
55. Bogenberger JM, DeLeon TT, Arora M, Ahn DH, Borad MJ. Emerging role of precision medicine in biliary tract cancers. NPJ Precis
Oncol 2018;2:21. DOI PubMed PMC
56. Wardell CP, Fujita M, Yamada T, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing
mutations. J Hepatol 2018;68:959-69. DOI PubMed
57. Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet 2015;47:1003-10. DOI PubMed
58. Chaisaingmongkol J, Budhu A, Dang H, et al; TIGER-LC Consortium. Common molecular subtypes among Asian hepatocellular
carcinoma and cholangiocarcinoma. Cancer Cell 2017;32:57-70.e3. DOI PubMed PMC
59. cBioPortal for Cancer Genomics. Available from: https://www.cbioportal.org/study/summary?id=chol_nccs_2013 [Last accessed on
16 Nov 2021].
60. Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of
cholangiocarcinoma. Hepatology 2014;59:1427-34. DOI PubMed
61. Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Hum Pathol 2014;45:1630-8. DOI PubMed
62. Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation
sequencing. Oncologist 2014;19:235-42. DOI PubMed PMC
63. Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in
intrahepatic cholangiocarcinoma. Nat Commun 2015;6:6087. DOI PubMed
64. Voss JS, Holtegaard LM, Kerr SE, et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment
decisions. Hum Pathol 2013;44:1216-22. DOI PubMed
65. Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov
2013;3:636-47. DOI PubMed PMC
66. Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in
FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet 2014;10:e1004135. DOI PubMed PMC
67. Putra J, de Abreu FB, Peterson JD, et al. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next
generation sequencing. Exp Mol Pathol 2015;99:240-4. DOI PubMed PMC
68. Zhu AX, Borger DR, Kim Y, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying
therapeutic targets. Ann Surg Oncol 2014;21:3827-34. DOI PubMed PMC
69. Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have
different outcomes. Gastroenterology 2013;144:829-40. DOI PubMed PMC
70. Farshidfar F, Zheng S, Gingras MC, et al; Cancer Genome Atlas Network. Integrative genomic analysis of cholangiocarcinoma
identifies distinct IDH-mutant molecular profiles. Cell Rep 2017;18:2780-94. DOI PubMed PMC
71. Nepal C, O'Rourke CJ, Oliveira DVNP, et al. Genomic perturbations reveal distinct regulatory networks in intrahepatic
cholangiocarcinoma. Hepatology 2018;68:949-63. DOI PubMed PMC
72. Job S, Rapoud D, Dos Santos A, et al. Identification of four immune subtypes characterized by distinct composition and functions of
tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology 2020;72:965-81. DOI PubMed PMC
73. Verlingue L, Malka D, Allorant A, et al. Precision medicine for patients with advanced biliary tract cancers: An effective strategy
within the prospective MOSCATO-01 trial. Eur J Cancer 2017;87:122-30. DOI PubMed
74. Lowery MA, Abou-alfa GK, Burris HA, et al. Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: results from the
cholangiocarcinoma dose escalation and expansion cohorts. J Clin Oncol 2017;35:4015-4015. DOI
75. Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced
cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 2021. DOI PubMed PMC
76. FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma Available from: https://www.fda.gov/drugs/resources-
information-approved-drugs/fda-approves-ivosidenib-advanced-or-metastatic-cholangiocarcinoma [Last accessed on 16 Nov 2021].
77. Javle M, Lowery M, Shroff RT, et al. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J
Clin Oncol 2018;36:276-82. DOI PubMed PMC
78. Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-
positive intrahepatic cholangiocarcinoma. Br J Cancer 2019;120:165-71. DOI PubMed PMC
79. Vogel A, Sahai V, Hollebecque A, et al. FIGHT-202: a phase II study of pemigatinib in patients (pts) with previously treated locally
advanced or metastatic cholangiocarcinoma (CCA). Ann Oncol 2019;30:v876. DOI
80. Jain A, Borad MJ, Kelley RK, et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precision
Oncology 2018. DOI
81. Javle MM, Sadeghi S, El-khoueiry AB, et al. A retrospective analysis of post second-line chemotherapy treatment outcomes for
patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions. J Clin Oncol 2020;38:4591. DOI PubMed
82. Abou-alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma
(CCA): update of FIGHT-202. J Clin Oncol 2021;39:4086. DOI
83. Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients
with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov 2017;7:252-63. DOI PubMed PMC
84. Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-
positive intrahepatic cholangiocarcinoma. Cancer Discov 2019;9:1064-79. DOI PubMed PMC